Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.40 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29337465 | 1.00 | LMNA (0.45) | LMNANOTUMIDH1ERCC1ERCC4 | |
| SCHEMBL9888714 | 0.87 | RXRA (0.47) | LMNANOTUMIDH1ERCC1ERCC4 | |
| SCHEMBL19732418 | 0.84 | NOTUM (0.42) | LMNANOTUMIDH1ERCC1ERCC4 | |
| SCHEMBL18793689 | 0.84 | NOTUM (0.42) | LMNANOTUMIDH1ERCC1ERCC4 | |
| SCHEMBL8215541 | 0.81 | NOTUM (0.55) | NOTUMKDM5BLRRK2POLBKDM4E | |
| SCHEMBL5567481 | 0.81 | NOTUM (0.55) | NOTUMKDM5BLRRK2POLBKDM4E | |
| SCHEMBL25611001 | 0.81 | MAPT (0.43) | LMNANOTUMIDH1ERCC1ERCC4 | |
| SCHEMBL5934873 | 0.78 | NOTUM (0.57) | LMNANOTUMERCC1ERCC4KDM4E | |
| SCHEMBL21583900 | 0.78 | LMNA (0.56) | LMNAERCC1ERCC4POLBMPO | |
| SCHEMBL5330796 | 0.77 | CYP2A6 (0.47) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135472-B2 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| US-20040106621-A1 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106621-A1 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | KCNQ3, KCNQ5, KCNQ2 | LMNA 1313/4885NOTUM 3749/4885IDH1 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.